Disclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015
|
|
- Gavin Long
- 6 years ago
- Views:
Transcription
1 Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident I do not have a vested interest in or affiliation with any corporate organization offering financial support or grant monies for this continuing education activity, or any affiliation with an organization whose philosophy could potentially bias my presentation 2 Objectives Upon completion of this activity, the pharmacist should be able to: Identify common complications of chemotherapy and assess the administration of relevant treatment Discuss applicable non-pharmacologic and pharmacologic treatment for cancer related pain Evaluate and recommend appropriate pharmacotherapy for the management of oncology related emergencies Objectives Upon completion of this activity, the technician should be able to: Examine causes or areas where medication errors frequently occur and the technician s role in minimizing medication errors Analyze potential barriers to rapid preparation and delivery of cancer related medications Outline suitable handling and storage techniques for hazardous medications 3 4 Oncologic Emergency 1 Classification of Emergencies 1 Oncologic emergency Complications resulting from a cancer itself or from the treatment of the cancer that requires immediate attention Can be classified by their system of origin: Metabolic Neurologic Cardiovascular Hematologic Infectious Classification Oncologic Emergency Metabolic Hypercalcemia Tumor Lysis Syndrome Neurologic Spinal Cord Compression Cardiovascular Superior Vena Cava Syndrome Hematologic Disseminated Intravascular Coagulation (DIC) Infectious Neutropenic Fever Septic Shock 5 6 1
2 Hypercalcemia 1 Management of Hypercalcemia 1 Results from increased bone resorption with calcium release into the extracellular fluid; renal clearance of calcium is also decreased Most common tumors associated with hypercalcemia are: Lung Breast Multiple myeloma Head and neck Renal cell Non-Hodgkin s lymphoma 7 Mild Corrected calcium less than 12 mg/dl May not require aggressive treatment Asymptomatic patients: hydration with normal saline followed by observation is an option Moderate Corrected calcium mg/dl Requires basic treatment of clinical symptoms 8 Management of Hypercalcemia 1 Tumor Lysis Syndrome (TLS) 1 Severe Corrected calcium greater than 14 mg/dl Patient is usually symptomatic Requires aggressive inpatient treatment Treatment options Hydration with normal saline Loop diuretics Bisphosphonates Calcitonin Steroids Phosphate Dialysis Cyclooxygenase inhibitors 9 1. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007; 4(2): doi: /ijms Available from 10 TLS Management 1,2 Spinal Cord Compression 1,2 Primary management is prevention with intravenous hydration (NaCl), sodium bicarbonate, and allopurinol Rasburicase (Elitek ) recombinant urate oxidase converts uric acid into allantoin Considered for patients at high risk of developing tumor lysis syndrome or inability to take allopurinol Direct extension from a metastasis in the vertebral body Signs and symptoms include Back pain Weakness Paresthesias Unsteady gait Loss of bowel and bladder function Treatment: dexamethasone and radiation therapy or surgery 2. Cervantes A., Chirivella I. Oncologic emergencies. Annals of Oncology 15 (Supplement 4): iv299 iv306, Kaplan, Marcelle, (2006). Understanding and Managing Oncologic Emergencies: A resource for nurses. Oncology Nursing Society, Philadelphia 12 2
3 Superior Vena Cava Syndrome 1 Disseminated Intravascular Coagulation (DIC) 1 Blood flow through the superior vena cava is compressed Causes decreased venous return to the heart, decrease in cardiac output, and increase in venous congestion and edema Treatment includes Chemotherapy/radiation Stent placement Diuretics Corticosteroids Thrombolytic agents 13 Inappropriate activation of the coagulation cascade, resulting in thrombosis and hemorrhage Solid tumors are associated with chronic DIC Two pathways Extrinsinc Intrinsic Treatment includes: Treat underlying problem Plasmapheresis Hemodynamic support IV fluids Oxygen Low dose Heparin May reverse the clot formation 14 Neutropenic Fever 1 MASCC Risk Index 1 Neutropenia: ANC of 500/mm 3 or less or a count of < 1000/mm 3 with a predicted decrease to < 500/mm 3 during the next 48 hours Fever: single oral temperature of 101 F or more or a temperature of F or more for at least 1 hour Fever is often the only indicator National Comprehensive Cancer Network (NCCN). Supportive Care: Febrile Neutropenia (Version ) Neutropenic Fever Treatment 1 Neutropenic Fever Treatment 1 First approach IV monotherapy First approach PO therapy Imipenem-Cilastatin (Primaxin ) Ciprofloxacin (Cipro ) + Amoxicillin/Clavulanate (Augmentin ) Meropenem (Merrem ) Allergy to penicillin - Ciprofloxacin (Cipro ) + Clindamycin (Cleocin ) Ceftazidime (Fortaz ) Cefepime (Maxipime ) Allergy to penicillin - Aztreonam (Azactam ) + Vancomycin (Vancocin ) Second approach IV dual therapy Aminoglycoside plus anti- pseudomonal penicillin OR an extended spectrum antipseudomonal cephalosporin Ciprofloxacin plus anti- pseudomonal penicillin Third approach for therapy Combination of monotherapy or dual therapy plus IV Vancomycin for specific indications - Not used as initial therapy because of vancomycin resistant organisms 1. National Comprehensive Cancer Network (NCCN). Supportive Care: Febrile Neutropenia (Version ) National Comprehensive Cancer Network (NCCN). Supportive Care: Febrile Neutropenia (Version )
4 Criteria for Therapy Discontinuation 1 Negative cultures for 48 hours Afebrile for 24 hours Evidence of marrow recovery (increase in ANC to >1000 cells/µl) It is acceptable to send an afebrile patient home for marrow recovery if the patient was a low risk patient 1. National Comprehensive Cancer Network (NCCN). Supportive Care: Febrile Neutropenia (Version ) Septic Shock 1 Sepsis: bodily response to infection Two of the following Temperature > F or < 96.8 F HR > 90 bpm RR > 20 bpm WBC >12,000 or < 4,000, or > 10% immature bands Severe sepsis: hypo-perfusion with hypotension or organ dysfunction Septic shock: persistent hypotension with organ dysfunction 20 Septic Shock Treatment 1 Acute Supportive Care 1 Blood, throat, wound, and urine cultures Labs (CBC, Chemistry, Coagulation), ABGs, CXR, EKG Fluids to improve perfusion/increase blood pressure Antibiotics Oxygen Electrolyte replacement 21 Interventions that help the patient achieve comfort but do not affect the course of the disease Acute Supportive Care Chemotherapy induced nausea and vomiting (CINV) Extravasation Thrombocytopenia Anemia Cancer-related pain 22 Chemotherapy Induced Nausea and Vomiting(CINV) 1,2 Basic Definitions: Nausea: discomfort that may or may not precede vomiting; decreased gastric tone and peristalsis Retching: dry heaves Vomiting: ejection of gastric contents through the mouth Acute onset Delayed onset Chemotherapy Induced Nausea and Vomiting(CINV) 1,2 Basic Definitions Anticipatory vomiting/nausea: triggered by sights, smells, or sounds Breakthrough emesis: vomiting occurs despite prophylactic treatment; requires rescue medications Refractory: emesis occurs during treatment when prophylactic treatment has failed in previous cycles
5 Management of CINV 1,2 High Emetogenic Potential IV Agents 1,2 Prophylaxis is key! Administer prophylactic anti-emetics before moderately or highly emetogenic agents Make sure anti-emetic regimen is appropriate based on the emetogenicity of the agent For select chemotherapy agents, schedule anti-emetics for delayed nausea and vomiting Greater than 90% frequency of emesis AC (combination defined as either doxorubicin or epirubicin with cyclophosphamide) Carmustine > 250 mg/m 2 Cisplatin 50 mg/m 2 Cyclophosphamide >1500 mg/m 2 Dacarbazine Doxorubicin > 60 mg/m 2 Epirubicin > 90 mg/m 2 Ifosfamide 10 g/m 2 Mechlorethamine Moderate Emetogenic Potential IV Agents 1,2 Low Emetogenic Potential IV Agents 1,2 Aldesleukin > million IU/m 2 Amifostine > 300 mg/m % frequency of emesis Dactinomycin Daunorubicin Arsenic trioxide Doxorubicin < 60 mg/m 2 Azacitidine Idarubicin Bendamustine Ifosfamide < 10 g/m 2 Busulfan Interferon alfa 10 million IU/m 2 Carboplatin Carmustine 250 mg/m 2 Irinotecan Melphalan Cisplatin < 50 mg/m 2 Methotrexate 250 mg/m 2 Clofarabine Cyclophosphamide 1500 mg/m 2 Oxaliplatin Temozolomide 10-30% frequency of emesis Aldesleukin 12 million IU/m 2 Ixabepilone Amifostine 300 mg Methotrexate > 50 mg/m 2, < 250 mg/m 2 Cabazitaxel Mitomycin Cytarabine (low dose) mg/m 2 Mitoxantrone Docetaxel Paclitaxel Doxorubicin (liposomal) Paclitaxel-albumin Eribulin Pemetrexed Etoposide Penostatin Fluorouracil Romidepsin Floxuridine Thiotepa Gemcitabine Topotecan Cytarabine > 200 mg/m 2 Interferon alfa > 5 < 10 million IU/m Alemtuzumab Minimal Emetogenic Potential IV Agents 1,2 < 10% frequency of emesis Ipilimumab Asparaginase Methotrexate 50 mg/m 2 Bevacizumab Bleomycin Bortezomib Cetuximab Cladribine (2-chlorodeoxyadenosine) Cytarabine < 100mg/m 2 Decitabine Denileukin diftitox Dexrazoxane Fludarabine Interferon alfa 5 million IU/m 2 Nelarabine Ofatumumab Panitumumab Pegasparagase Rituximab Temsirolimus Trastuzumab Valrubicin Vinblastine Vincristine Vinorelbine 29 Altretamine Busulfan ( 4 mg/day) Etoposide Lomustine (single day) Bexarotene Busulfan (< 4 mg/day) Cyclophosphamide (< 100 mg/m 2 /day) Hydroxyurea Fludarabine Melphalan Mercaptopurine Vorinostat Topotecan Prophylaxis Recommended for Oral Agents Cyclophosphamide ( 100 mg/m 2 /day) Estramustine Procarbazine As Needed for Oral Agents Temozolomide (> 75 mg/m 2 /day) Capecitabine Chlorambucil Dasatinib, Erlotinib, Imatinib, Lapatinib, Nilotinib, Sorafenib, Sunitinib, Pazopanib, Vandetanib, Gefitinib Everolimus Tretinoin Methotrexate Lenalidomide, Thalidomide, Temozolomide ( 75 mg/m 2 /day) Thioguanine 30 5
6 CINV Treatment Options CINV Treatment 1,2 Drug Day 1 Day 2 Day 3 Day 4 Aprepitant (Fosaprepitant IV) AND 125 mg PO or 150 mg IV 80 mg PO 80 mg PO N/A Dexamethasone AND Ondansentron OR Granisetron OR Dolasetron OR Palonosetron 12 mg PO/IV 12 mg PO/IV mg PO or 8-16 mg IV 2 mg PO or 0.01 mg/kg IV (max 1 mg) or Sancuso Patch 8 mg PO 8 mg PO 8 mg PO 8 mg PO BID N/A N/A N/A N/A N/A N/A 100 mg PO N/A N/A N/A 0.25 mg IV 8 mg PO 8 mg PO BID Extravasation 1 Extravasation Definition: the leakage or escape of a drug/solution from a vein or inadvertent injection into surrounding tissues Three types of chemotherapy agents Non-vesicant Irritant Vesicant Non-DNA binding DNA binding 1. Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group, Management of Extravasation 1 Stop the infusion and disconnect the IV tubing Apply a topical compress (warm or cold depending on offending agent) Next, antidote should be infused and any pharmacologic treatments should be given as well Photograph site of initial injury and on all other visits Follow-up visits are needed for assessment Medication Cisplatin (Platinol ) Extravasation Potential Vesicant at concentration > 0.4 mg/ml Local Care Cold Compress Teniposide (Vumon ) Irritant/Vesicant Cold Compress, Warm Compress Anthracyclines (Daunorubicin, Doxorubicin, Idarubicin) Antidote Sodium Thiosulfate vs. Dimethyl Sulfoxide (DMSO) Hyaluronidase Vesicants Cold Compress Dexrazoxane vs. DMSO Etoposide (Vepesid ) Vesicant/Irritant Warm Compress Hyaluronidase Mitomycin (Mutamycin ) Mitoxantrone (Novantrone ) Vesicant None or Cold Compress Dimethyl Sulfoxide vs. Sodium Thiosulfate Irritant/Vesicant Cold Compress Dezrazoxane vs. DMSO Oxaliplatin (Eloxatin ) Irritant/Vesicant None None Paclitaxel (Taxol ) Irritant/Vesicant Cold Compress Hyaluronidase Vinca Alkaloids (Vinblastine, Vincristine, Vinorelbine) Vesicants Warm Compress Hyaluronidase 1. Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group, Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group,
7 Medication Bleomycin (Blenoxane ) Carboplatin (Parplatin ) Extravasation Potential Local Care Antidote Irritant Cold Compress None Irritant at > 10mg/mL Cold Compress DMSO Carmustine (BiCNU ) Vesicant/Irritant Cold Compress None Cyclophosphamide (Cytoxan ) Dacarbazine (DTIC- DOME ) Dactinomycin (Cosmegen ) Irritant Cold Compress None Irritant/Vesicant Cold Compress DMSO Vesicant Cold Compress DMSO Docetaxel (Taxotere ) Vesicant/Irritant Cold Compress None Fluorouracil (Adrucil ) Topotecan (Hycamtin ) Irritant None Possibly DMSO Irritant Cold Compress None Medication Gemcitabine (Gemzar ) Extravasation Potential Local Care Antidote Irritant None None Ifosfamide (Ifex ) Irritant Cold Compress Possibly DMSO Irinotecan (Camptosar ) Mechlorethamine (Mustargen ) Irritant Ice None Vesicant None Sodium thiosulfate Melphalan (Alkeran ) Irritant/Vesicant Cold Compress None 1. Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group, Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group, Thrombocytopenia 1 Anemia 1 Platelet count < 100,000/mm 3 Oprelvekin (interleukin-11) Approved for the prevention of severe thrombocytopenia in patients undergoing chemotherapy for non-myeloid malignancies Daily subcutaneous injection, beginning 6 24 hours after completion of chemotherapy Continue until a post-nadir platelet count of 50,000 cells/mm 3 or greater Dosing beyond 21 days is not recommended Must be discontinued at least 2 days before the next cycle of chemotherapy 39 Decreased RBC production due to chemotherapy Treatment: Erythropoiesis stimulating agents (ESA s) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Only if hemoglobin < 10 g/dl and duration of chemotherapy 2 months Discontinue after completion of chemotherapy 40 Cancer Related Pain Principles 1 When available, the oral route is preferred The dose and analgesic drug should match the severity of pain suffered by patient Pain medications should always be administered on a scheduled basis, not as needed If more than two as-needed doses are required for breakthrough pain in a 24-hour period, consider modifying the regimen Provide medications to prevent adverse events (e.g., constipation) Pain Rating Scales 1 Use pain scales to evaluate pain intensity at baseline and throughout regimen Pain is subjective; best evaluated by the patient
8 WHO Analgesic Ladder 1 Medication Errors 1 Preventable event that may cause patient harm or inappropriate medication use while the medication is in control of the healthcare professional, patient, or consumer Potential error: mistake in prescribing, dispensing, or planned administration that is corrected prior to actual medication administration 1. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Can Fam Physician.2010 Jun;56(6): Accessed: American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50: Types of Medication Errors 1 Common Causes of Medication Errors 1 Type Definition Prescribing Error Incorrect drug selection; illegible script Omission Error Failure to do something correctly Wrong Time Error Giving a drug outside predefined time Unauthorized Drug Error Giving a drug not authorized by MD Improper Dose Error Dose is greater or less than that ordered Wrong Dosage Form Error Administration of a different dosage form Wrong Drug Preparation Error Incorrectly formulated or manipulated Wrong Administration Technique Error Inappropriate procedure or technique Deteriorated Drug Error Giving an expired drug Monitoring Error Failure to assess prescribed regimens Compliance Error Non-adherence to regimen Other Errors Those who don t fall in above categories 1. American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50: Ambiguous strength designation on labels or in packaging Drug product nomenclature (look-alike or sound-alike names, use of lettered or numbered prefixes and suffixes in drug names) Equipment failure or malfunction Illegible handwriting Improper transcription 1. American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50: Inaccurate dosage calculation Inadequately trained personnel Inappropriate abbreviations used in prescribing Labeling errors Excessive workload Lapses in individual performance Medication unavailable 46 Prevention of Medication Errors 1 Five Rights Work area should have adequate lighting, low noise, and few distractions Drugs should be organized to reduce confusion (LASA, Tall man lettering, etc.) Remembering do not use abbreviations Adhering to pharmacy policies and procedures Prioritizing workload Recognizing strength and dosing regimen of chemotherapy Identifying weaknesses in processes Potential Barriers 1 Inappropriate dosage calculations Reading the label incorrectly Grabbing the wrong drug for preparation Taking on more than one task at a time Using inappropriate admixtures Lack of knowledge Sterile processing before drug preparation Inappropriate work area 1. Pharmacy Technician s Letter. Medication Safety: Strategies for Preventing Medication Errors. Volume 2013, Course Number Pharmacy Technician s Letter. Medication Safety: Strategies for Preventing Medication Errors. Volume 2013, Course Number
9 Handling and Storage 1 Handling and Storage 1 Make sure pharmacy is up to date with USP 797 Wear double gloving for all activities involving hazardous drugs Personal protective equipment (PPE) must be worn at all times in the area where the preparation of chemotherapy takes place Hazardous drug spill kits, containment bags, and disposal containers must be available in all areas where hazardous drugs are handled Storage areas for hazardous drugs must have distinctive labels Hazardous drugs should be stored in an area with sufficient general exhaust ventilation to dilute and remove any airborne contaminants Hazardous drugs placed in inventory must be protected from potential breakage by storage in bins that have high fronts and on shelves that have guards to prevent accidental falling 1. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63: American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63: Summary Summary Oncologic emergencies can be classified by their system of origin Before the administration of therapy for hypercalcemia, analyze if therapy is indicated Rasburicase (Elitek ) is only used for tumor lysis syndrome in high risk patients and those unable to take allopurinol Treatment for spinal cord compression includes dexamethasone to decrease the inflammation Superior vena cava syndrome causes a decrease in cardiac output DIC is the inappropriate activation of the coagulation cascade Fever is often the only indicator of neutropenic fever Septic shock is defined as persistent hypotension with organ dysfunction Prophylaxis is key in the management of CINV There are three types of chemotherapy agents for extravasation: non-vesicant, irritant, vesicant Do not use Oprelvekin for more than 21 days for thrombocytopenia ESA s for anemia can only be used if hemoglobin is < 10 g/dl Pain scales are utilized to evaluate pain severity One way to prevent medication errors is by remembering the five rights Knowing potential barriers to chemotherapy preparation can help prevent them from happening All hazardous drugs have a medication safety data sheet (MSDS) During tumor lysis syndrome, there is an increase in uric acid and potassium but a decrease in phosphorous Causes of medication errors include labeling errors, look-alike sound-alike medications, inaccurate dosage calculations, and illegible handwriting FALSE Increase in uric acid, potassium, AND phosphorous TRUE
10 The following CINV regimen is standard treatment for cancer medications with high risk Aprepitant/Fosaprepitant PLUS Ondansetron PLUS Lorazepam PLUS Dexamethasone FALSE Lorazepam is not considered standard therapy for high CINV risk treatment 55 Basic storage of hazardous agents include Keeping storage areas appropriately ventilated, well lit, and at a consistent temperature TRUE 56 Performing ratio and proportion calculations mentally is the quickest and safest way to ensure that the patient gets their chemotherapy in a timely fashion Chemotherapy agents can be divided into three main categories: non-vesicants, irritants, and vesicants TRUE FALSE Chemotherapy calculations should never be performed mentally Literature Sources Kaplan, Marcelle, (2006). Understanding and Managing Oncologic Emergencies: A resource for nurses. Oncology Nursing Society, Philadelphia Norris, LB. Oncology Supportive Care. ACCP Updates in Therapeutics, Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007; 4(2): doi: /ijms Available from Cervantes A., Chirivella I. Oncologic emergencies. Annals of Oncology 15 (Supplement 4): iv299 iv306, 2004 National Comprehensive Cancer Network (NCCN). Supportive Care: Febrile Neutropenia (Version ). Literature Sources Basch E., Prestrud AA., Hesketh PJ., et al. Antiemtics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 29: Ackerman M., Allen C., Armbruster W., et al. Extravasation Guideliness. Children s Oncology Group, Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Can Fam Physician.2010 Jun;56(6): Accessed: American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63: Pharmacy Technician s Letter. Medication Safety: Strategies for Preventing Medication Errors. Volume 2013, Course Number
Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationPatient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationSARASOTA MEMORIAL HOSPITAL
SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE DATE: REVIEWED: PAGES: 03/86 7/18 1 of 13 PS1094 ISSUED FOR: Nursing RESPONSIBILITY: RN Chemo Qualified PURPOSE: To provide the RN with specific steps
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationIntroduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationGuidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More informationREFERENCES American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:
Ordering and Handling Applies To: UNM Hospitals Responsible Department: Pharmacy Revised: 8/2017 Procedure Patient Age Group: ( ) N/A (X) All Ages ( )Newborns ( )Pediatric ( )Adult DESCRIPTION/OVERVIEW
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationAntineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea
Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationREVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Pediatr Blood Cancer 2011;57:191 198 REVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients L. Lee Dupuis, MScPhm, ACPR, FCSHP,
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationTitle Developed By. Implementation Contact person(s) Review Date Group Responsible. NICaN Policy: Management of Chemotherapy Extravasation; Version 3
Title Developed By Management of Chemotherapy Extravasation NICaN Regional Pharmacy Group Version History Version 3: 2009 (See appendix 6) Version 2: January 2006 Version 1: June 2005 Consultation Period
More informationHodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data
Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationHospice Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationOncology Skills Checklist
_ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values
More informationCOG Supportive Care Endorsed Guidelines Version date: December 11, 2017
COG Supportive Care Endorsed Guidelines The COG Supportive Care Endorsed Guidelines are comprised of -based guidelines which have been developed by other organizations endorsed by the Children s Oncology
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationSupportive Care for Patients with Cancer
3:15pm - 4:15pm: Breakout 4 - Oncology Option A: Supportive Care for Patients with Cancer ACPE UAN 0107-0000-10-021-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives for Pharmacists:
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Characterization of the generated hipsc lines a) Western blot analysis indicating the efficient downregulation of p53 upon knockdown in three hipsc lines (
More information